Drug Profile
Research programme: inhaled therapeutic - AGI Therapeutics
Alternative Names: AGI-350Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AGI Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in Ireland (Inhalation, Aerosol)
- 23 Mar 2011 Preclinical trials in Lung disorders in Ireland (Inhalation)